purify in quantities sufficient for analysis in cell culture (data not shown). Following these results, and based on the observation that ZFP DNA-binding domains carry a net positive charge (Fig. 1a) , we hypothesized that ZFNs might penetrate the cell in the absence of additional modification. We expressed in Escherichia coli ZFNs designed to target the CCR5 gene and lacking any transduction domain and then purified them to homogeneity from either the soluble or the insoluble fractions (Supplementary Fig. 1 ). In vitro analysis confirmed that functional ZFN proteins with similar DNA cleavage profiles could be obtained by either method (Supplementary Fig. 2 and Supplementary Note).
To determine the ability of ZFN proteins to penetrate cells and stimulate mutagenesis, we generated a fluorescence-based reporter system to measure ZFN-induced DSBs (Fig. 1b) . This system uses an integrated EGFP gene whose expression has been interrupted by a frameshift mutation introduced by a strategically placed ZFN cleavage site. ZFN proteins that penetrate reporter cells can induce DSBs at this target site and drive the introduction of small insertions and deletions in the EGFP locus by NHEJ. Because NHEJ is a stochastic process, approximately one-third of these mutational events (+2, +5, +8,… bp or −1, −4, −7,… bp) will restore the frame and EGFP function.
Direct application of ZFN proteins to reporter cells resulted in a dose-dependent increase in EGFP fluorescence, with maximum activity (6% EGFP-positive cells) achieved after treatment with 2 µM ZFN proteins (Fig. 1c) . By comparison, transient transfection of ZFN expression plasmids under saturating conditions resulted in ~7% EGFP-positive cells (Supplementary Fig. 3 ). We observed no difference in activity between ZFN proteins purified from the soluble fraction or inclusion bodies ( Supplementary  Fig. 4) . At all ZFN concentrations evaluated, the use of transient hypothermic culture conditions 9 enhanced the efficiency of mutagenesis nearly twofold (Fig. 1c,d ). Extended periods of incubation (>60 min) did not increase the frequency of genome editing (Supplementary Fig. 5 ). Consecutive protein treatments, however, did increase the percentage of EGFP-positive cells (Fig. 1d,e) . Notably, repeated treatment with ZFN proteins over 3 d using transient hypothermic conditions yielded ~12% EGFP-positive cells (Fig. 1e) . Sequence analysis of isolated EGFPpositive cells verified targeted mutagenesis, confirming the presence of the anticipated ZFN-induced insertions and deletions in the EGFP locus (Fig. 1f) .
To determine the contribution of each ZFN component to cellular penetration, we incubated cells with fluorescently labeled ZFN or FokI cleavage domain proteins (Supplementary Fig. 6 ). We observed fluorescence in cell lysate following treatment with ZFN-in the presence or absence of a nuclear localization ZFNs are fusions of the nonspecific cleavage domain from the FokI restriction endonuclease with custom-designed Cys 2 -His 2 zinc-finger proteins (ZFPs) 1 . These chimeric nucleases induce sequence-specific DNA double-strand breaks (DSBs) that can be repaired by error-prone nonhomologous end joining (NHEJ) to yield small alterations at targeted genomic loci. This strategy has enabled highly efficient gene disruption in numerous cell types 2, 3 and model organisms 4, 5 and has facilitated the progress of targeted gene therapy in humans 6, 7 . Despite these advances and more recent methodological improvements [8] [9] [10] , there remains a need for new methods that can improve the utility of these enzymes. The development of safe and effective ZFN delivery methods is of particular importance, as the deficiencies of ZFN gene-delivery systems may hinder the continued advancement of this technology. In particular, viral vectors 11 are time consuming to produce and can be associated with undesirable side effects, such as insertional mutagenesis, whereas nonviral DNA and mRNA delivery systems are restricted to certain cell types and have been reported to show toxicity 12, 13 and low efficiency 14 . To address this problem, we set out to develop a simple alternative to conventional ZFN delivery systems by investigating the direct delivery of purified ZFN proteins to cells.
We began by introducing protein transduction domains into the established ZFN architecture. For this, we genetically fused either the cell-penetrating peptide sequence from the HIV-1 TAT protein or a polyarginine motif to the N termini of ZFNs designed to target the human chemokine (C-C motif) receptor 5 (CCR5) gene 6 . These ZFNs, however, were consistently difficult to express or sequence-but not with the FokI cleavage domain, suggesting that zinc-finger domains facilitate cellular internalization.
We evaluated the efficacy of this approach for the disruption of endogenous genes by treating human embryonic kidney (HEK) 293 and human acute monocytic leukemia (THP1) cell lines, as well as primary adult human dermal fibroblast (HDF) and primary CD4 + T cells, with ZFN proteins targeting the CCR5 gene. These ZFNs used the highactivity Sharkey cleavage domain 10 . Analysis of DNA isolated from each cell type with the Surveyor nuclease assay showed efficient and dose-dependent disruption of the endogenous CCR5 gene (Fig. 2a) . HEK293 and HDF cells subjected to three consecutive treatments with 2 µM ZFN proteins showed genedisruption frequencies >24%, whereas CD4 + cells subjected to three consecutive treatments with 0.5 µM ZFN proteins had genedisruption frequencies >8%. As observed in the reporter system, the frequency of gene disruption increased with repeated protein npg treatments (Supplementary Fig. 7 ). Sequence analysis of cloned CCR5 alleles amplified from each treated cell type confirmed the presence of ZFN-induced insertions and deletions in the CCR5 gene (Supplementary Fig. 8 ).
To investigate the cleavage specificity of ZFNs using this approach, we evaluated the activity of the CCR5 ZFN proteins against nine previously described 6,15 off-target cleavage sites in HEK293 cells (Supplementary Fig. 9 ). In direct comparison to Lipofectamine-mediated transient transfection of ZFN expression plasmids, we found that cells subjected to consecutive protein treatments showed a marked decrease in ZFN activity at every off-target site, including the CCR2 locus. Notably, there was no detectable ZFN activity at three of these loci. Western blot analysis showed complete degradation of delivered ZFN proteins <4 h after application, whereas cells transfected with ZFN expression plasmids produced high-levels of protein continuously from 16 h to 72 h after transfection (Supplementary Fig. 10 ). These results indicate that the differences in cleavage specificity could be attributable to the short half-lives of transduced ZFN proteins and that limiting the duration of ZFN exposure inside cells is a viable method for minimizing toxicity 16 . Consistent with these degradation kinetics, cells treated with ZFN proteins showed maximum activity at 8 h, whereas cells expressing ZFNs from plasmid DNA showed maximum activity at 48 h (Supplementary Fig. 10) .
To examine the breadth of this technique, we treated Chinese hamster ovary (CHO) cells with ZFN proteins designed to target the dihydrofolate reductase (DHFR) gene 2 . These ZFNs used various specialized cleavage domains, including Sharkey and the evolutionarily optimized DS/RR obligate heterodimeric architecture 10 . We observed reduced levels of functional DHFR protein, as determined by fluorescein-labeled methotrexate-based flow cytometry analysis, in CHO cells following three consecutive treatments with DHFR ZFN proteins (Fig. 2b) . Notably, CHO cells incubated with ZFNs containing Sharkey mutations showed a >12% reduction in functional DHFR. Sequence analysis of cloned DHFR alleles amplified from cells treated with ZFN proteins validated these percentages and confirmed the presence of ZFN-induced insertions and deletions in the DHFR gene (Supplementary Fig. 11 ). Examination of DHFR protein levels in expanded clonal populations indicated biallelic DHFR gene-disruption frequencies >7% (Supplementary Fig. 12) , showing that constitutive ZFN expression from plasmid DNA is not required for high-frequency biallelic modifications and can instead be achieved using directly applied ZFN proteins.
We observed no appreciable toxicity in HEK293 or HDF cells treated with ZFN proteins (Fig. 2c) or in CHO cells incubated with ZFN proteins containing either the wild-type cleavage domain or the DS/RR architecture (Fig. 2d) . However, we measured decreased proliferation in CHO and THP1 suspension cells incubated with >1 µM ZFN proteins containing Sharkey mutations (Fig. 2c,d) . We also observed, qualitatively, toxicity in CD4 + cells subjected to consecutive treatments with >1 µM ZFN proteins, suggesting that sensitive cell types may require protein to be administered in consecutive low doses to minimize potential toxic effects.
We have demonstrated the intrinsic cell-penetrating capabilities of the standard ZFN architecture. Furthermore, we have shown that direct delivery of ZFNs as proteins can be used to disrupt the expression of endogenous genes in a variety of mammalian cell types, including primary CD4 + T cells and primary adult human dermal fibroblasts, which are frequently used to generate induced pluripotent stem cells. In contrast to methods that require ZFN expression from DNA, ZFN protein delivery leads to comparatively fewer off-target cleavage events and does not carry the risk of insertional mutagenesis. Thus, this method is suitable for genome-editing applications in which minimizing cellular toxicity or maintaining genetic integrity is of particular importance, such as the in vitro modeling of human diseases and the ex vivo modification of nontransformed human cell types. We show that this method can also be used to modify difficultto-transfect cell types, including patient-derived leukemia cell lines and primary human lymphocytes, supporting the use of this technique in place of viral-mediated gene delivery for inducing gene knockouts in cultured cells for reverse genetics and drug discovery. As methods for engineering cell permeability into proteins improve, we anticipate that protein delivery and the benefits afforded therein will be extended to other designer nucleases, including TALENs.
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acknoWledgments We thank C. Gersbach for contributing to preliminary studies, P. Ikrenyi for technical assistance and A. Mercer for discussion of the manuscript. Table 2 ). ZFN protein expression and purification. ZFN expression plasmids were transformed into chemically competent E. coli BL21 (DE3) pGro7 cells (Stratagene). A single colony was added to 10 ml of LB medium in the presence of 50 µg ml −1 kanamycin, 100 µg ml −1 chloramphenicol and 1% glucose. Bacteria were grown overnight at 37 °C with shaking. The following day, 500 ml of LB medium supplemented with 100 µM ZnCl 2 , 50 µg ml −1 kanamycin, 100 µg ml −1 chloramphenicol and 0.2% glucose was inoculated with 5 ml of the overnight culture and incubated at 30 °C with shaking. The culture was grown to an optical density at 600 nm (OD 600 ) of 0.4 and then incubated at room temperature with shaking until the OD 600 reached 0.8. Protein synthesis was then induced with 0.1 mM isopropyl β-d-1-thiogalactopyranoside (IPTG). After 4 h, cells were harvested by centrifugation at 2,000 RCF for 20 min at 4 °C, and the pellet was resuspended in native lysis buffer (50 mM Tris-HCl, 500 mM NaCl, 100 µM ZnCl 2 , 1 mM PMSF, 1 mM MgCl 2 , 1 mM β-mercaptoethanol, 10 mM imidazole, 0.2% Triton X-100 and 10% glycerol, pH 8.0). Cells were lysed using standard sonication conditions, and the soluble fraction was isolated by centrifugation at 18,000 RCF for 30 min at 4 °C. ZFN proteins were purified using Ni-NTA agarose resin (QIAGEN) and eluted with 500 mM imidazole in the presence of 50 mM Tris-HCl, 500 mM NaCl, 100 µM ZnCl 2 and 10% glycerol at pH 8.0. Each protein was concentrated and dialyzed against storage buffer (20 mM HEPES, 90 µM ZnCl 2 , 150 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , pH 7.4) and assessed for purity by SDS-PAGE. The protein yield after purification was determined to be between 0.5 mg l −1 and 1.0 mg l −1 .
Inclusion-body purification. ZFN proteins were also purified from inclusion bodies using an alternative method. Following the inoculation of 500 ml of LB medium with 5 ml of the overnight culture, cells were incubated at 37 °C with shaking until the OD 600 reached 0.4, and then at room temperature with shaking until the OD 600 reached 0.9. Protein synthesis was induced by addition of 0.4 mM IPTG and 4 mM arabinose. After 16 h, cells were harvested by centrifugation at 2,000 RCF for 20 min at 4 °C, and the pellet was resuspended in lysis buffer (50 mM TrisHCl, 150 mM NaCl, 0.1% Triton X-100, pH 8.0). Cells were lysed using standard sonication conditions and centrifuged at 10,000 RCF for 30 min at 4 °C. Inclusion bodies were then washed with lysis buffer and centrifuged at 10,000 RCF for 30 min at 4 °C. This process was repeated twice and was followed by a procedure designed to enhance protein yield and purity: inclusion bodies were (i) washed with cold water, (ii) centrifuged at 10,000 RCF for 30 min at 4 °C, (iii) resuspended in PBS, (iv) centrifuged as in step (ii), (v) incubated with solubilization buffer (PBS, 500 mM l-arginine, 90 µM ZnCl 2 , 1 mM MgCl 2 , pH 7.4) for 3 h at 4 °C and (vi) centrifuged as in step (ii). L-Arginine was included to facilitate refolding of recombinant proteins from inclusion bodies 17 . Following this procedure, the inclusion-body supernatant was isolated and protein purity was assessed by SDS-PAGE. The protein yield after purification was determined to be between 3 mg l −1 and 5 mg l −1 .
In vitro cleavage analysis. Cleavage analysis was performed as described 10 .
Reporter system construction and analysis. The EGFP reporter systems used in this study were generated using the Flp-In System (Invitrogen) and constructed as described 10 with the following exception: the CCR5 ZFN cleavage site was amplified with the overlapping oligonucleotides 5′ midEGFP-CCR5 and 3′ midEGFP-CCR5. Reporter cells were analyzed by flow cytometry as described 10 .
Cell culture. HEK293, THP1, HDF (Invitrogen) and CHO cells were seeded onto 24-well plates at a density of 1 × 10 5 cells per well and established in a humidified 5% CO 2 atmosphere at 37 °C. Peripheral blood mononuclear cells (PBMCs) were obtained from anonymous healthy blood donors through the Scripps Research Institute Normal Blood Donor Program. Primary CD4 + T cells were purified from PBMCs using the RosetteSep Human CD4 + T Cell Enrichment Cocktail (Stem Cell Technologies) according to the manufacturer's instructions. CD4 + cells were seeded onto 96-well plates at a density of 1 × 10 5 cells per well and established in a humidified 5% CO 2 atmosphere at 37 °C. HEK293 and HDF cells were maintained in DMEM containing 10% (vol/vol) FBS and 1% (vol/vol) Antibiotic-Antimycotic (Anti-Anti; Gibco). THP1, CHO and CD4 + cells were maintained in RPMI containing 10% (vol/vol) FBS and 1% (vol/vol) Anti-Anti. CHO cells were maintained with HT supplement (100 µM sodium hypoxanthine and 160 µM thymidine; (Invitrogen)) after treatment with ZFN proteins. ZFN protein treatments. ZFN proteins were prepared for treatment as follows: ZFNs purified from the soluble fraction were diluted into serum-free medium containing 90 µM ZnCl 2 at pH 7.4. ZFNs purified from inclusion bodies were diluted into serum-free medium containing 100 mM L-arginine and 90 µM ZnCl 2 at pH 7.4. At 24 h after seeding, cells were washed with serum-free medium and treated with ZFN proteins for 1 h at 37 °C. After treatment, cells were washed and maintained at 37 °C with npg
